IDEAYA Biosciences Overview
- Year Founded
-
2015

- Status
-
Public
- Employees
-
124

- Stock Symbol
-
IDYA

- Investments
-
1
- Share Price
-
$23.00
- (As of Friday Closing)
IDEAYA Biosciences General Information
Description
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
Contact Information
Website
www.ideayabio.comCorporate Office
- 7000 Shoreline Court
- Suite 350
- South San Francisco, CA 94080
- United States
Corporate Office
- 7000 Shoreline Court
- Suite 350
- South San Francisco, CA 94080
- United States
IDEAYA Biosciences Stock Performance
As of 07-Feb-2025, IDEAYA Biosciences’s stock price is $23.00. Its current market cap is $1.99B with 86.4M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$23.00 | $23.96 | $22.10 - $47.73 | $1.99B | 86.4M | 919K | -$2.33 |
IDEAYA Biosciences Financials Summary
As of 30-Sep-2024, IDEAYA Biosciences has a trailing 12-month revenue of $3.92M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 1,976,585 | 1,826,814 | 491,902 | 651,108 |
Revenue | 3,922 | 23,385 | 50,931 | 27,941 |
EBITDA | (220,539) | (131,929) | (58,987) | (47,236) |
Net Income | (178,120) | (112,961) | (58,655) | (49,762) |
Total Assets | 1,239,873 | 649,316 | 387,969 | 381,347 |
Total Debt | 18,796 | 2,872 | 3,482 | 5,181 |
IDEAYA Biosciences Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
IDEAYA Biosciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
IDEAYA Biosciences Comparisons
Industry
Financing
Details
IDEAYA Biosciences Competitors (66)
One of IDEAYA Biosciences’s 66 competitors is CaroGen, a Venture Capital-Backed company based in Farmington, CT.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
CaroGen | Venture Capital-Backed | Farmington, CT | ||||
Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
858 Therapeutics | Venture Capital-Backed | San Diego, CA | ||||
Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
IDEAYA Biosciences Patents
IDEAYA Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240327399-A1 | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof | Pending | 09-Dec-2022 | ||
AU-2023279251-A1 | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof | Pending | 01-Jun-2022 | ||
US-20230303556-A1 | Piperazine substituted indazole compounds as inhibitors of parg | Pending | 23-Mar-2022 | ||
AU-2023239344-A1 | Piperazine substituted indazole compounds as inhibitors of parg | Pending | 23-Mar-2022 | ||
EP-4496795-A1 | Piperazine substituted indazole compounds as inhibitors of parg | Pending | 23-Mar-2022 | C07D417/14 |
IDEAYA Biosciences Signals
IDEAYA Biosciences Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
IDEAYA Biosciences Investments (1)
IDEAYA Biosciences’s most recent deal was a Corporate Asset Purchase with Novartis (IDE196 Global Rights in Basel, Switzerland) for . The deal was made on 01-Sep-2018.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Novartis (IDE196 Global Rights in Basel, Switzerland) | 01-Sep-2018 | Corporate Asset Purchase | Buildings and Property |
IDEAYA Biosciences ESG
Risk Overview
Risk Rating
Updated July, 29, 2023
33.66 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Pharmaceuticals
Subindustry
of 425
Rank
Percentile

IDEAYA Biosciences FAQs
-
When was IDEAYA Biosciences founded?
IDEAYA Biosciences was founded in 2015.
-
Where is IDEAYA Biosciences headquartered?
IDEAYA Biosciences is headquartered in South San Francisco, CA.
-
What is the size of IDEAYA Biosciences?
IDEAYA Biosciences has 124 total employees.
-
What industry is IDEAYA Biosciences in?
IDEAYA Biosciences’s primary industry is Drug Discovery.
-
Is IDEAYA Biosciences a private or public company?
IDEAYA Biosciences is a Public company.
-
What is IDEAYA Biosciences’s stock symbol?
The ticker symbol for IDEAYA Biosciences is IDYA.
-
What is the current stock price of IDEAYA Biosciences?
As of 07-Feb-2025 the stock price of IDEAYA Biosciences is $23.00.
-
What is the current market cap of IDEAYA Biosciences?
The current market capitalization of IDEAYA Biosciences is $1.99B.
-
What is IDEAYA Biosciences’s current revenue?
The trailing twelve month revenue for IDEAYA Biosciences is $3.92M.
-
Who are IDEAYA Biosciences’s competitors?
CaroGen, Vedanta Biosciences, 858 Therapeutics, Sorrento Therapeutics, and CytomX Therapeutics are some of the 66 competitors of IDEAYA Biosciences.
-
What is IDEAYA Biosciences’s annual earnings per share (EPS)?
IDEAYA Biosciences’s EPS for 12 months was -$2.33.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »